Table 2 Cytokine levels at baseline before and at the beginning of the first clinical symptoms of veno-occlusive-disease and organ specific graft-versus-host disease
Post-transplant-adverse event | Serum level | Before post-transplant adverse event | Post-transplant adverse event | |||
|---|---|---|---|---|---|---|
Median | Range | Median | Range | P-value | ||
VOD | IL-6 pg/ml | 3.150 | 2.0 – 28.0 | 69.850 | 7.7 – 197.0 | 0.0313 |
IL-8 pg/ml | 18.4 | 5.0 – 54.2 | 105 | 13.6 – 200.0 | 0.0156 | |
IL-10 pg/ml | 3.55 | 2.4 – 4.7 | 6.20 | 4.3 – 20.4 | n.d. | |
sIL-2R U/ml | 1519.0 | 397 – 3796 | 3218.0 | 1934 – 4666 | 0.3750 | |
IL-1 ß ng/ml | 0.260 | 0.15 – 0.39 | 0.335 | 0.1 – 0.47 | 0.7500 | |
TNF-α pg/ml | 8.00 | 7.5 – 21.8 | 22.30 | 10.5 – 103 | 0.0313 | |
Acute liver GvHD | IL-6 pg/ml | 2.0 | 2.0 – 2.0 | 28.1 | 27.5 – 28.7 | n.d. |
IL-8 pg/ml | 20 | 5.0 – 35.0 | 526.5 | 460.0 – 593.0 | n.d. | |
IL-10 pg/ml | 2.00 | 2.0 – 2.0 | 135.90 | 98.8 – 173.0 | n.d. | |
sIL-2R U/ml | 823 | 823 – 823 | 5705.0 | 2483 – 8927 | n.d. | |
TNF-α pg/ml | 4.00 | 4.0 – 4.0 | 50.35 | 32.2 – 68.5 | n.d. | |
Acute intestinal GvHD II-IV | IL-6 pg/ml | 3.3 | 2.0 – 26.0 | 24.3 | 2.0 – 254.0 | 0.0010 |
IL-8 pg/ml | 26.65 | 5.0 – 5702 | 33.6 | 10.7 – 460.0 | 0.2036 | |
IL-10 pg/ml | 3.20 | 2.0 – 7.9 | 46.25 | 12.4 – 173 | 0.0039 | |
sIL-2R U/ml | 823.5 | 397 – 2393 | 2321.0 | 1296 – 3586 | 0.0020 | |
IL-1 ß ng/ml | 0.21 | 0.22 – 0.41 | 0.21 | 0.17 – 0.31 | 0.5000 | |
TNF-α pg/ml | 7.20 | 5.2 – 19.90 | 28.05 | 12.4 – 90.6 | 0.0020 | |
Acute skin GvHD II-IV | IL-6 pg/ml | 2.15 | 2.0 – 7.4 | 8.3 | 2.5 – 83.2 | 0.0010 |
IL-8 pg/ml | 10.4 | 5.0 – 40.0 | 11.9 | 5.0 – 47.9 | 0.2783 | |
IL-10 pg/ml | 4.90 | 2.0 – 7.7 | 6.60 | 1.9 – 278.0 | 0.9453 | |
sIL-2R U/ml | 930.5 | 397 – 2831 | 1846.0 | 918 – 8540 | 0.0049 | |
IL-1 ß ng/ml | 0.18 | 0.1 – 0.39 | 0.34 | 0.23 – 0.36 | 0.5000 | |
TNF-α pg/ml | 7.20 | 4.0 – 17.0 | 18.20 | 11.2 – 35.7 | 0.0020 | |